GSK-1838705A | B2026

GSK-1838705A is a potent small-molecule kinase inhibitor that inhibits IGF-IR and IR (insulin receptor) with IC₅₀s of 2.0 and 1.6 nM, respectively. It also inhibits anaplastic lymphoma kinase (ALK). It causes complete regression of ALK-dependent tumors in vivo at well-tolerated doses.

GSK-1838705A is a potent small-molecule kinase inhibitor that inhibits IGF-IR and IR (insulin receptor) with IC₅₀s of 2.0 and 1.6 nM, respectively. It also inhibits anaplastic lymphoma kinase (ALK). It causes complete regression of ALK-dependent tumors in vivo at well-tolerated doses.

B2026 | GSK-1838705A DataSheet

Alternate Name/Synonyms: 2-((2-((1-(2-(dimethylamino)acetyl)-5-methoxyindolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-6-fluoro-N-methylbenzamide

Appearance: Beige solid

Formulation: N/A

CAS Number: 1116235-97-2

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₇H₂₉FN₈O₃

Molecular Weight: 532.57

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO (>15 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent ALK inhibitor

MDL Number: N/A

PubChem CID: 25182616

SMILES: CNC(=O)C1=C(C=CC=C1F)NC2=NC(=NC3=C2C=CN3)NC4=C(C=C5CCN(C5=C4)C(=O)CN(C)C)OC

InChi: InChI=1S/C27H29FN8O3/c1-29-26(38)23-17(28)6-5-7-18(23)31-25-16-8-10-30-24(16)33-27(34-25)32-19-13-20-15(12-21(19)39-4)9-11-36(20)22(37)14-35(2)3/h5-8,10,12-13H,9,11,14H2,1-4H3,(H,29,38)(H3,30,31,32,33,34)

InChi Key: HZTYDQRUAWIZRE-UHFFFAOYSA-N